Cepheid MTB/RIF Assay

The Florida Department of Health, Bureau of Public Health Laboratories (BPHL) has a need to purchase FDA-approved assay kits that are compatible with the Cepheid GeneXpert system. Specifically, the BPHL is seeking to acquire a semi-quantitative nested real-time PCR assay for the detection of Mycobacterium Tuberculosis complex DNA in sputum samples and the detection of Rifampin resistance associated mutations of the rpoB gene in samples from patients at risk for rifampin resistance. The BPHL is requesting authorization to purchase, as a single source, the Cepheid Xpert GMTB/RIF-US-10 Assay kits for a 3-year term. The estimated dollar amount for this purchase is $214,200.00. The justification for the single-source acquisition is that the Cepheid assay kits are the only FDA-approved kits compatible with the BPHL's Cepheid GeneXpert system and testing algorithm. Prospective vendors are requested to provide information regarding their ability to supply the required commodities or services, and the agency will provide notice of its intended decision to enter a single-source purchase contract if it determines that the commodities or services are available only from a single source.

This contracting opportunity is limited to the Leon County jurisdiction within the state of Florida. There are no set-aside designations or restrictions on the types of organizations that can respond. Cepheid is the incumbent vendor and sole manufacturer and supplier of the required GeneXpert technology and assays. The budget for this procurement is estimated at $214,200.00 for the 3-year term.